[go: up one dir, main page]

AR036098A1 - Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos - Google Patents

Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos

Info

Publication number
AR036098A1
AR036098A1 ARP020102303A ARP020102303A AR036098A1 AR 036098 A1 AR036098 A1 AR 036098A1 AR P020102303 A ARP020102303 A AR P020102303A AR P020102303 A ARP020102303 A AR P020102303A AR 036098 A1 AR036098 A1 AR 036098A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heterocyclyl
cycloalkyl
preparation
Prior art date
Application number
ARP020102303A
Other languages
English (en)
Inventor
Helmut Heinrich Buschmann
Englberger Werner Guenter Dr
Tieno Germann
Michael Haurand
Hennies Hagen-Heinrich Dr
Corinna Maul
Sundermann Bernd Dr
Joerg Holenz
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR036098A1 publication Critical patent/AR036098A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)

Abstract

Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos de la fórmula general (1), en forma de sus racematos, sus estereoisómeros puros, particularmente enantiómeros o diasteréomeros o en forma de mezcla de sus estereoisómeros, particularmente de los enantiómeros y diasteréomeros, en cualquier proporción; en la forma representada o en la forma de sus ácidos o sus bases o en forma de sus sales, particularmente sales fisiológicamente tolerables, con particular preferencia en forma de sus clorhidratos, o en forma de sus solvatos, particularmente hidratos; en la cual: R1 y R2 representan independientemente entre sí H, alquilo C1-8, cicloalquilo C3-10, (alquil C1-12)-cicloalquilo C3-10, arilo, (alquil C1-12)-arilo, heterociclilo, (alquil C1-12)-heterociclilo o NH-C(=O)-arilo, siendo al menos uno de los radicales R1 y R2 distinto de H, o R1 y R2 representan conjuntamente -(CR4R5)m-(CR6R7)n-Y-(CR8R9)p-(CR10R11)q- siendo respectivamente m, n, p y q alguno de los números 0, 1, 2, 3, 4 ó 5, con la condición que m + n es 1, y que p + q es 1, o representan -CH2-CH2-C(arilo)=CH-CH2-; R3 representa H, SO2R12 o COR13; R4, R5, R6, R7, R8, R9, R10 y R11 representan independientemente entre sí H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo o C(=O)R14; Y representa CR15R16, NR17 u O; R12 y R13 representan independientemente entre sí alquilo C1-10, cicloalquilo C3-10, (alquil C1-6)-cicloalquilo C3-10, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo o NR18R19; R14 representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo u OR20; R15 y R16 representan independientemente entre sí H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo, o C(=O)R21; R17 representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo o C(=O)R22; R18 y R19 representan independientemente entre sí representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, o (alquil C1-6)-heterociclilo; R20 representa representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, o (alquil C1-6)-heterociclilo; R21 representa representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo u OR23; R22 representa representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, (alquil C1-6)-heterociclilo u OR24; y R23 y R24 representan independientemente entre sí representa H, alquilo C1-10, cicloalquilo C3-8, (alquil C1-6)-cicloalquilo C3-8, arilo, (alquil C1-6)-arilo, heterociclilo, o (alquil C1-6)-heterociclilo; procedimientos para su preparación, su uso para la preparación de medicamentos y medicamentos que contienen estos compuestos. Estos compuestos son adecuados para la terapia del dolor y eventualmente para el caso de dolores neuropáticos y crónicos.
ARP020102303A 2001-06-25 2002-06-19 Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos AR036098A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10130020A DE10130020A1 (de) 2001-06-25 2001-06-25 Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate

Publications (1)

Publication Number Publication Date
AR036098A1 true AR036098A1 (es) 2004-08-11

Family

ID=7689008

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102303A AR036098A1 (es) 2001-06-25 2002-06-19 Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos

Country Status (29)

Country Link
US (2) US8048890B2 (es)
EP (1) EP1401841B1 (es)
JP (1) JP4410554B2 (es)
KR (1) KR100917112B1 (es)
CN (1) CN1315840C (es)
AR (1) AR036098A1 (es)
AT (1) ATE302782T1 (es)
AU (1) AU2002310768B2 (es)
BR (1) BR0211053A (es)
CA (1) CA2451859C (es)
CO (1) CO5540301A2 (es)
CZ (1) CZ20033432A3 (es)
DE (2) DE10130020A1 (es)
DK (1) DK1401841T3 (es)
EC (1) ECSP034924A (es)
ES (1) ES2245402T3 (es)
HU (1) HU228774B1 (es)
IL (2) IL159544A0 (es)
MX (1) MXPA03012013A (es)
NO (1) NO332217B1 (es)
NZ (1) NZ530689A (es)
PE (1) PE20030146A1 (es)
PL (1) PL214290B1 (es)
PT (1) PT1401841E (es)
RU (1) RU2296128C2 (es)
SI (1) SI1401841T1 (es)
SK (1) SK287390B6 (es)
WO (1) WO2003000699A1 (es)
ZA (1) ZA200400489B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
CN1674907A (zh) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 瑞波西汀在治疗热潮红中的用途
DE102004023635A1 (de) * 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102005016170A1 (de) * 2005-04-07 2006-10-12 Grünenthal GmbH 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) * 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) * 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US9340558B2 (en) 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8580808B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
EP2498600B1 (en) * 2008-10-31 2016-03-02 Pain Therapeutics, Inc. Filamin a-binding anti-inflammatory analgesic
US20100279996A1 (en) * 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
JP5874878B2 (ja) * 2009-01-26 2016-03-02 イスラエル インスティトゥート フォー バイオロジカル リサーチ 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
US8580809B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
DK2882428T3 (en) 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
US20170197971A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
CO2018008450A2 (es) 2016-01-13 2018-09-20 Gruenenthal Gmbh Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
SI3402783T1 (sl) 2016-01-13 2020-10-30 Gruenenthal Gmbh Derivati 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
TWI635082B (zh) 2016-01-13 2018-09-11 歌林達有限公司 ３－（（雜－）芳基）－８－胺基－２－側氧－１,３－二氮雜－螺－［４.５］－癸烷衍生物
AU2017206909B2 (en) 2016-01-13 2020-07-09 Grünenthal GmbH 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10988449B2 (en) 2017-04-12 2021-04-27 Il Dong Pharmaceutical Co., Ltd. Isoxazole derivatives as nuclear receptor agonists and uses thereof
CN109793713B (zh) * 2019-03-26 2021-05-28 李世系 一种用于麻醉的短效催眠镇静的药物组合物及其注射剂制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127065C (es) * 1964-04-22
GB1227365A (es) * 1968-07-29 1971-04-07
JPH02164882A (ja) * 1988-12-20 1990-06-25 Yamanouchi Pharmaceut Co Ltd スピロ化合物及びその中間体
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
DE4024415A1 (de) * 1990-08-01 1992-02-06 Hoechst Ag Verfahren zur herstellung von 1-oxa-3,8-diaza-4-oxo-spiro-(4,5)decan- verbindungen
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
DE19528472A1 (de) 1995-08-03 1997-02-06 Boehringer Ingelheim Kg Neues Verfahren zur Herstellung von Norbenzomorphan einer Zwischenstufe bei Herstellung von pharmazeutisch wertvollen Benzomorphanderivaten, insbesondere von (-)-(1R,5S,S"R)-3'-Hydroxy-2-(2-methoxypropyl-)-5,9,9-trimethyl-6,7 benzomorphan
CA2233204A1 (en) 1995-09-29 1997-04-03 Joseph A. Jakubowski Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
JP2001527513A (ja) * 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
ES2226475T3 (es) 1998-11-18 2005-03-16 Basf Aktiengesellschaft Procedimdiento para la obtencion de 2-alquil-3-(4,5- dihidroisoxazol -3- il)- halogenbencenos.
KR20030000243A (ko) 2001-06-22 2003-01-06 이 석 민 동물사료 제조방법 및 그에 적합한 기밀 플라스틱백발효용기
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate

Also Published As

Publication number Publication date
WO2003000699A8 (de) 2003-11-20
DK1401841T3 (da) 2005-09-19
CA2451859A1 (en) 2003-01-03
CN1315840C (zh) 2007-05-16
PL214290B1 (pl) 2013-07-31
NO332217B1 (no) 2012-07-30
US8048890B2 (en) 2011-11-01
KR100917112B1 (ko) 2009-09-11
RU2296128C2 (ru) 2007-03-27
CA2451859C (en) 2011-06-14
AU2002310768B2 (en) 2007-01-11
BR0211053A (pt) 2004-07-20
US20040192916A1 (en) 2004-09-30
ECSP034924A (es) 2004-02-26
CN1547584A (zh) 2004-11-17
HUP0400810A3 (en) 2007-11-28
IL159544A0 (en) 2004-06-01
WO2003000699A1 (de) 2003-01-03
EP1401841B1 (de) 2005-08-24
HK1064669A1 (en) 2005-02-04
NO20035730L (no) 2004-02-19
US20110224172A1 (en) 2011-09-15
KR20040008226A (ko) 2004-01-28
ATE302782T1 (de) 2005-09-15
MXPA03012013A (es) 2004-03-26
ES2245402T3 (es) 2006-01-01
IL159544A (en) 2009-05-04
CZ20033432A3 (cs) 2004-05-12
ZA200400489B (en) 2004-10-14
HU228774B1 (en) 2013-05-28
JP2004536095A (ja) 2004-12-02
EP1401841A1 (de) 2004-03-31
DE10130020A1 (de) 2003-12-04
PE20030146A1 (es) 2003-03-15
PT1401841E (pt) 2005-11-30
SK15702003A3 (sk) 2004-07-07
HUP0400810A2 (hu) 2004-07-28
JP4410554B2 (ja) 2010-02-03
RU2004100823A (ru) 2005-06-20
US8557796B2 (en) 2013-10-15
NO20035730D0 (no) 2003-12-19
SK287390B6 (sk) 2010-08-09
NZ530689A (en) 2005-07-29
CO5540301A2 (es) 2005-07-29
PL367748A1 (en) 2005-03-07
SI1401841T1 (sl) 2006-02-28
DE50204037D1 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
AR036098A1 (es) Derivados de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
AR041941A1 (es) Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
AR082994A1 (es) Derivados de pirazina como bloqueadores del canal epitelial de sodio
AR034244A1 (es) Derivados de 4-aminopiperidina y su uso como medicamento
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
NO20050065L (no) Kjemiske forbindelser
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
NO20051223L (no) Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5.
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
NO20062032L (no) Derivater av N-[fenyl(pyrrolidin-2-yl)-metyl]benzamid og N-[(azepan-2-yl)fenylmetyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske midler
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR019789A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
AR032778A1 (es) Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento
AR041546A1 (es) Agentes antibacterianos de tetrahidroquiolina triciclicos
BG101402A (en) Apoliprotein-b synthesis inhibitors
DE69210875D1 (de) Piperidinderivate, Verfahren zu deren Herstellung und deren therapeutische Anwendung
HUP0303801A2 (hu) Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP0222693A3 (en) 3-oxadiazolyl and 3-carboxylic-acid beta-carboline derivatives, their preparation and their use as medicaments
PE20030705A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
AR048959A1 (es) Amidas sustituidas del acido tiofencarboxilico; su obtencion y su uso como medicamentos con efecto antitrombotico.
AR041895A1 (es) Derivados de 4 (fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales

Legal Events

Date Code Title Description
FB Suspension of granting procedure